Atara Biotherapeutics, Inc. Form DEFA14A April 30, 2019

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. __)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to § 240.14a-12

Atara Biotherapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

1. Title of each class of securities to which transaction applies:

Edgar Filing: Atara Biotherapeutics, Inc. - Form DEFA14A

2.	Aggregate number of securities to which transaction applies:
3.	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
4.	Proposed maximum aggregate value of transaction:
5.	Total fee paid:
Fee p	paid previously with preliminary materials.
whic	ck box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for h the offsetting fee was paid previously. Identify the previous filing by registration statement number, or form or Schedule and the date of its filing.
6.	Amount Previously Paid:
7.	Form, Schedule or Registration Statement No.:
8.	Filing Party:
9.	Date Filed:

*** Exercise Your Right to Vote ***

Important Notice Regarding the Availability of Proxy Materials for the

Stockholder Meeting to Be Held on June 27, 2019

ATARA BIOTHERAPEUTICS, INC.

ATARA BIOTHERAPEUTICS, INC.
611 GATEWAY BLVD., SUITE 900
SOUTH SAN FRANCISCO, CA 94080

Meeting Information

Meeting Type: Annual Meeting **For holders as of:** April 29, 2019

Date: June 27, 2019 **Time:** 9:00 AM PDT

Location: 2430 Conejo Spectrum St. Thousand Oaks, CA 91320

You are receiving this communication because you hold shares in the above named company.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

See the reverse side of this notice to obtain proxy materials and voting instructions.

Before You Vote

How to Access the Proxy Materials

Proxy Materials Available to VIEW or RECEIVE:

1. Notice & Proxy Statement 2. Form 10-K

How to View Online:

Have the information that is printed in the box marked by the arrow (located on the following page) and visit: www.proxyvote.com.

How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

1) *BY INTERNET*: www.proxyvote.com 2) *BY TELEPHONE*: 1-800-579-1639

3) BY E-MAIL*: sendmaterial@proxyvote.com

* If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow (located on the following page) in the subject line.

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before June 13, 2019 to facilitate timely delivery.

How To Vote

Please Choose One of the Following Voting Methods

Vote In Person: Many stockholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a

Edgar Filing: Atara Biotherapeutics, Inc. - Form DEFA14A

ballot to vote these shares.

Vote By Internet: To vote now by Internet, go to *www.proxyvote.com*. Have the information that is printed in the box marked by the arrow available and follow the instructions.

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

Voting items		
The Board of Directors recommends	you	vote

FOR the following:

1. Election of Directors

Nominees

- 01 Matthew K. Fust 02
- 02 Roy Baynes, M.D., Ph.D.

The Board of Directors recommends you vote FOR the following proposal:

2. To approve, on an advisory basis, the compensation of the Company s named executive officers, as disclosed in the proxy statement.

The Board of Directors recommends you vote 1 YEAR on the following proposal:

- **3.** To approve, on an advisory basis, the frequency of stockholder advisory votes on executive compensation. **The Board of Directors recommends you vote FOR the following proposal:**
 - **4.** To ratify the selection of Deloitte & Touche, LLP as the Company s independent registered public accounting firm for the fiscal year ending December 31, 2019.

NOTE: Such other matters that may properly come before the meeting or any adjournment or postponement thereof will be voted on by the proxy holders in their discretion.